Mesenchymal stem cells (MSCs) and regulatory T cells (Tregs) form a key immunoregulatory axis essential for maintaining immune homeostasis and treating autoimmune diseases, transplant rejection, and inflammatory disorders. Although both MSCs and Tregs have been individually studied, a clear synthesis of how MSCs regulate Treg function across distinct mechanistic layers and disease contexts remains lacking. MSCs regulate Treg differentiation, expansion, and functional stability through paracrine signaling, intercellular contact–dependent pathways, extracellular vesicle (EV)–mediated transfer of microRNAs (miRNAs) and proteins, mitochondrial transfer, and metabolic and epigenetic reprogramming. These mechanisms restore Th17/Treg balance, suppress inflammation, and promote tissue repair. Preclinical studies demonstrate strong therapeutic potential in multiple immune–mediated diseases; however, clinical translation remains limited. Unlike previous studies, this review integrates soluble and exosomal signaling pathways, compares shared and disease‐specific regulatory mechanisms, and critically evaluates MSC source variability, methodological limitations, and causes of clinical inconsistency. It aims to provide a conceptual framework to guide future mechanistic studies and clinical development of MSC–Treg–based therapies.
Chronic obstructive pulmonary disease (COPD) remains a major global health challenge. This study explored the therapeutic mechanisms of Huangjing (Polygonati Rhizoma) and Gegen (Puerariae Lobatae Radix), two food-medicine homologous herbs with potential in COPD management. Integrating network pharmacology, serum pharmacochemistry, molecular docking, and experimental validation, we identified 239 shared targets and the PI3K/AKT pathway as a potential key mechanism. UHPLC Q-Exactive Orbitrap MS revealed 66 compounds, 14 of which were absorbed into circulation. In vivo, Huangjing-Gegen appeared to improve lung function (PaO2 increased by 28.3%, PaCO2 decreased by 22.7%), alleviate pathology, and reduce inflammation through downregulating TNF-α (by 21.4%), IL-6 (by 30.7%), and IL-1β (by 29.3%) and suppressing the EGFR-PI3K/AKT pathway. Molecular docking provided supportive evidence for strong binding between absorbed puerarin derivatives and core targets. These findings suggest that the PI3K/AKT pathway may play a central role in the therapeutic effects of Huangjing-Gegen against COPD.
Shaoqing Zhu, Jiaruo Li, Lin Chu et al.· Natural Product Research· 0 citations